Clinical trials: Body Weight
Chronic Weight Management
A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults
APD356-A001-402 is a multicenter, double-blind, randomized, parallel-group pilot study of 12-week duration in overweight and obese adults.
- Trial name
- NCT01987427
- Testing
- lorcaserin + phentermine-HCl
- Where
- 13 sites in United States
- Volunteers
- 344 people
- Sponsor
- Eisai Inc.
Overweight, Obesity
Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity
This study will look at participants' body weight from the start to the end of the study. The study will last for about 1½ years.
- Trial name
- STEP 8 (NCT04074161)
- Testing
- Semaglutide, Liraglutide
- Where
- 19 sites in United States
- Volunteers
- 338 people
- Sponsor
- Novo Nordisk A/S
Obesity
Pivotal Aspiration Therapy With Adjusted Lifestyle Therapy Study
This research study is being performed to find out if a new device, AspireAssist Aspiration Therapy System, can help people with obesity to lose weight without causing too many side effects.
- Trial name
- PATHWAY (NCT01766037)
- Testing
- Aspiration Therapy (AspireAssist), Lifestyle Therapy
- Where
- 10 sites in United States
- Volunteers
- 171 people
- Sponsor
- Aspire Bariatrics, Inc.
Type 2 Diabetes Mellitus
Body Weight Effects on Glucophage's Efficacy in Chinese Diagnosed T2DM Patients
The purpose of this study is to investigate the effect of the baseline body mass index (BMI) on the response to Glucophage XR monotherapy in glycemic control in Chinese patients with newly diagnosed type 2 diabetes
- Trial name
- NCT00778622
- Testing
- Metformin XR
- Where
- 14 sites in China
- Volunteers
- 371 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Chronic
A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C
This 4-arm study will compare the efficacy and safety of PEGASYS induction and maintenance dosing, versus standard fixed dosing in combination with Copegus, and the efficacy and safety of higher dose versus standard dose Copegus…
- Trial name
- NCT00394277
- Testing
- peginterferon alfa-2a, Ribavirin
- Where
- 184 sites in United States, Belgium and 13 more
- Volunteers
- 1,175 people
- Sponsor
- Hoffmann-La Roche
Inflammation
A Study of Tomato Products and Disease Risk
The purpose of this research study is to test whether certain compounds in tomatoes will help reduce factors in the subject's blood associated with disease risk.
- Trial name
- TOM (NCT00966550)
- Testing
- Tomato, Non-tomato
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
Obesity
Multi-Center Pre-Bariatric Weight Loss Study
The purpose of the study is to evaluate the safety and efficacy of the GI Sleeve in patients who require weight loss prior to their Bariatric surgery.
- Trial name
- NCT00469391
- Testing
- GI Sleeve Implantable weight loss device (EndoBarrier)
- Where
- 4 sites in United States
- Volunteers
- 56 people
- Sponsor
- Morphic Medical Inc.
Atrial Fibrillation, Obesity
Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare
The overall objective of this analysis is to understand patient characteristics, the use of treatment, and clinical outcomes among obese (overweight) and severely obese patients with non-valvular atrial fibrillation (NVAF) who…
- Conditions
- Atrial Fibrillation, Obesity, Anticoagulants
- Trial name
- NCT04681482
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 107,383 people
- Sponsor
- Pfizer
Cachexia
SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)
To evaluate SUN11031 for subcutaneous injection compared to placebo in subjects with cachexia associated with Chronic Obstructive Pulmonary Disease (COPD) to determine the effect on physical performance and body composition.
- Trial name
- NCT00698828
- Testing
- SUN11031 20 μg/kg, SUN11031 40 μg/kg
- Where
- 43 sites in United States, Argentina and 4 more
- Volunteers
- 227 people
- Sponsor
- Daiichi Sankyo
Obesity, Diabetes Mellitus, Type 2
Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes
Single center, single-dose, randomized, placebo-controlled, dose-escalating study to evaluate, safety, tolerability, pharmacokinetics, and pharmacodynamics of escalating doses of ENT-03S in obese but otherwise healthy subjects…
- Trial name
- NCT05925920
- Testing
- ENT-03
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Metabolics Pharma
Obesity
Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity
The study aims to assess the safety and tolerability of maridebart cafraglutide as single and multiple doses in participants with obesity
- Trial name
- NCT04478708
- Testing
- maridebart cafraglutide
- Where
- 3 sites in United States
- Volunteers
- 110 people
- Sponsor
- Amgen
Metabolism and Nutrition Disorder, Obesity
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
This trial is conducted globally. The aim of this trial is to investigate safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus.
- Trial name
- NCT02453711
- Testing
- semaglutide, liraglutide
- Where
- 74 sites in United States, Australia and 6 more
- Volunteers
- 957 people
- Sponsor
- Novo Nordisk A/S
Obesity
Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity
This study looks at how well semaglutide helps people lose weight. This study will look at the change in the participants' body weight from the start to the end of the study.
- Trial name
- NCT04998136
- Testing
- Semaglutide 2.4 mg
- Where
- 16 sites in South Korea, Thailand
- Volunteers
- 150 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight
This study is open to adults, aged 18 to 75 years, with overweight or obesity. People with body mass index (BMI) of 27 or higher to join the study. People who have diabetes cannot participate.
- Trial name
- NCT04667377
- Testing
- BI 456906
- Where
- 43 sites in United States, Australia and 10 more
- Volunteers
- 387 people
- Sponsor
- Boehringer Ingelheim
Neuromuscular Blockade
Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146)
The purpose of this trial is to evaluate the safety and efficacy of Sugammadex when administered according to actual body weight (ABW) as compared to ideal body weight (IBW) for the reversal of both moderate and deep…
- Trial name
- NCT03346070
- Testing
- Sugammadex 2 mg/kg ABW, Sugammadex 2 mg/kg IBW, Sugammadex 4 mg/kg ABW
- Where
- 24 sites in United States, Austria and 3 more
- Volunteers
- 207 people
- Sponsor
- Merck Sharp & Dohme LLC
Obesity
Clinical Trial of Safety and Efficacy of New Dosage Schedule for Dietressa Drug in Treatment of Obese Patients
To assess safety of Dietressa in the dose of 6 tablets daily within 24 weeks in treatment of obese patients (BMI 35,0-39,9 kg/m2).
- Trial name
- NCT01570829
- Testing
- Dietressa
- Where
- 17 sites in Russia
- Volunteers
- 331 people
- Sponsor
- Materia Medica Holding
Obesity, Morbid
Swedish Adjustable Gastric Banding Observational Cohort Study
Longitudinal prospective cohort study of patients treated consecutively by SAGB in a sample of centers representative of this activity in France.
- Trial name
- NCT01183975
- Where
- France
- Volunteers
- 517 people
- Sponsor
- Ethicon Endo-Surgery (Europe) GmbH
Obesity
Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)
The fixed-dose combination of naltrexone 8mg and bupropion 90mg extended-release oral tablet is marketed under the trade name CONTRAVE® in the U.S.
- Trial name
- HOA (NCT06090461)
- Where
- United States
- Volunteers
- 31,889 people
- Sponsor
- Currax Pharmaceuticals
Obesity
A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)
Single ascending dose of HM15211 in healthy obese subjects.
- Trial name
- NCT03374241
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Overweight, Obesity
A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range
This study will look at how the investigational dose of semaglutide works in helping people with excess body weight, to lose weight.
- Trial name
- STEP12 (NCT06041217)
- Testing
- Semaglutide
- Where
- 21 sites in China, Taiwan
- Volunteers
- 242 people
- Sponsor
- Novo Nordisk A/S